Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $5.8 million.

  • Krystal Biotech's Change in Accured Expenses fell 2267.81% to $5.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.1 million, marking a year-over-year increase of 16162.12%. This contributed to the annual value of $14.1 million for FY2025, which is 16162.12% up from last year.
  • According to the latest figures from Q4 2025, Krystal Biotech's Change in Accured Expenses is $5.8 million, which was down 2267.81% from $5.9 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Change in Accured Expenses ranged from a high of $7.5 million in Q4 2024 and a low of -$5.2 million during Q1 2024
  • Over the past 5 years, Krystal Biotech's median Change in Accured Expenses value was $2.0 million (recorded in 2022), while the average stood at $1.6 million.
  • As far as peak fluctuations go, Krystal Biotech's Change in Accured Expenses skyrocketed by 62934.78% in 2022, and later plummeted by 27203.18% in 2023.
  • Krystal Biotech's Change in Accured Expenses (Quarter) stood at -$4.0 million in 2021, then soared by 153.64% to $2.2 million in 2022, then surged by 70.75% to $3.7 million in 2023, then soared by 103.18% to $7.5 million in 2024, then decreased by 22.68% to $5.8 million in 2025.
  • Its Change in Accured Expenses stands at $5.8 million for Q4 2025, versus $5.9 million for Q3 2025 and -$1.3 million for Q2 2025.